Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ProBioGen, Surface Oncology Sign Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

ProBioGen, Surface Oncology Sign Agreement

For the development and manufacture of an antibody for potential use in clinical trials

By: Betsy Louda

, Contract Pharma

ProBioGen AG has signed a second antibody development project with Surface Oncology Inc., an immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment.

 

Under the terms of the agreement Surface Oncology will contract with ProBioGen to develop and manufacture another antibody for potential use in clinical trials. ProBioGen will develop several stable cell lines in parallel, gradually reduce the candidate number and conclude with process development and GMP manufacturing for a single antibody product candidate. 

 

“We have worked together with Surface Oncology very well for quite a while and this is now our second potential clinical antibody project together,” said Gabriele Schneider, chief business officer, ProBioGen. “We have established a seamless team working across our companies and we are very pleased to continue to expand this relationship with Surface Oncology”.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics